Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Flurazepam
- Accession Number
- DB00690 (APRD00983)
- Type
- Small Molecule
- Groups
- Approved, Illicit, Investigational
- Description
A benzodiazepine derivative used mainly as a hypnotic. [PubChem]
- Structure
Structure for DB00690 (Flurazepam)
- Synonyms
- Flurazepam
- Flurazépam
- Flurazepamum
- Insumin
- External IDs
- ID 480 / Ro 5-6901
- Product Ingredients
Ingredient UNII CAS InChI Key Flurazepam Hydrochloride 7C4JH842IJ 36105-20-1 PUGVROXLRUQCAF-UHFFFAOYSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Dalmane Capsule 30 mg Oral Valeant Canada Lp Valeant Canada S.E.C. 1971-12-31 2016-07-08 Canada 
Dalmane Capsule 15 mg Oral Valeant Canada Lp Valeant Canada S.E.C. 1971-12-31 2016-07-08 Canada Flurazepam Capsule 30 mg Oral Aa Pharma Inc 1982-12-31 Not applicable Canada Flurazepam Capsule 15 mg Oral Aa Pharma Inc 1982-12-31 Not applicable Canada Flurazepam 15 Capsule 15 mg Oral Pro Doc Limitee 1982-12-31 Not applicable Canada Flurazepam 15mg Capsule Capsule 15 mg Oral Laboratoires Confab Inc Not applicable Not applicable Canada Flurazepam 30 Capsule 30 mg Oral Pro Doc Limitee 1982-12-31 Not applicable Canada Flurazepam 30mg Capsule Capsule 30 mg Oral Laboratoires Confab Inc Not applicable Not applicable Canada Som-pam Capsule 30 mg Oral Biomed Pharma 1981-12-31 Not applicable Canada Som-pam Capsule 15 mg Oral Biomed Pharma 1981-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Bio-flurazepam Capsule 30 mg Oral Biomed Pharma 2004-04-23 Not applicable Canada Bio-flurazepam Capsule 15 mg Oral Biomed Pharma 2004-04-23 Not applicable Canada Flurazepam Capsule 30 mg/1 Oral H.J. Harkins Company 1986-12-08 Not applicable US 
Flurazepam Capsule 15 mg/1 Oral Golden State Medical Supply 1986-12-08 2017-10-26 US Flurazepam Capsule 15 mg/1 Oral A S Medication Solutions 1986-12-08 2017-06-20 US 
Flurazepam Capsule 30 mg/1 Oral Rebel Distributors 1986-12-08 Not applicable US Flurazepam Capsule 30 mg/1 Oral West Ward Pharmaceutical 1986-12-08 Not applicable US Flurazepam Capsule 30 mg/1 Oral Preferreed Pharmaceuticals Inc. 2012-01-27 Not applicable US 
Flurazepam Capsule 30 mg/1 Oral A S Medication Solutions 1986-12-08 2017-06-20 US Flurazepam Capsule 15 mg/1 Oral bryant ranch prepack 1986-12-08 2018-05-31 US 
- International/Other Brands
- Dalmadorm (Meda) / Dalmadorm medium (Meda) / Felison (SIT) / Flunox (Teofarma) / Sompan (I.C.N.) / Valdorm (Valeas)
- Categories
- Anti-Anxiety Agents
- Benzazepines
- Benzodiazepines and benzodiazepine derivatives
- Benzodiazepinones
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 Enzyme Inhibitors
- GABA Agents
- GABA Modulators
- Hypnotics and Sedatives
- Nervous System
- Neurotransmitter Agents
- P-glycoprotein/ABCB1 Inhibitors
- Psycholeptics
- Psychotropic Drugs
- Tranquilizing Agents
- UNII
- IHP475989U
- CAS number
- 17617-23-1
- Weight
- Average: 387.878
Monoisotopic: 387.151368285 - Chemical Formula
- C21H23ClFN3O
- InChI Key
- SAADBVWGJQAEFS-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
- IUPAC Name
- 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
- SMILES
- CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F
Pharmacology
- Indication
For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
- Associated Conditions
- Pharmacodynamics
Flurazepam, a benzodiazepine derivative, is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time.
- Mechanism of action
Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization.
- Absorption
Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
- Volume of distribution
- Not Available
- Protein binding
83%
- Metabolism
Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form
- Route of elimination
Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.
- Half life
The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
- Clearance
- Not Available
- Toxicity
Coma, confusion, low blood pressure, sleepiness
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Flurazepam is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Aceprometazine. Approved Acetyl sulfisoxazole The metabolism of Flurazepam can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Adipiplon The risk or severity of adverse effects can be increased when Flurazepam is combined with Adipiplon. Investigational Afatinib The serum concentration of Afatinib can be increased when it is combined with Flurazepam. Approved Agomelatine The risk or severity of adverse effects can be increased when Flurazepam is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Flurazepam is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Flurazepam is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Flurazepam is combined with Alfentanil. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Flurazepam is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Flurazepam is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Flurazepam is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Flurazepam. Approved, Illicit, Investigational Ambroxol acefyllinate The therapeutic efficacy of Flurazepam can be decreased when used in combination with Ambroxol acefyllinate. Experimental, Investigational Aminophylline The therapeutic efficacy of Flurazepam can be decreased when used in combination with Aminophylline. Approved Amiodarone The metabolism of Flurazepam can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Flurazepam is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Flurazepam is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Flurazepam is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Flurazepam is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Flurazepam is combined with Amperozide. Experimental Apalutamide The serum concentration of Flurazepam can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Flurazepam can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Flurazepam is combined with Asenapine. Approved Atazanavir The metabolism of Flurazepam can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Flurazepam can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Flurazepam is combined with Azaperone. Investigational, Vet Approved Azelastine Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Flurazepam is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Flurazepam is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Benzocaine. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Flurazepam is combined with Benzyl alcohol. Approved Boceprevir The metabolism of Flurazepam can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Flurazepam can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Flurazepam can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Flurazepam. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Flurazepam. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Flurazepam is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved Bromazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Flurazepam is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Flurazepam is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Flurazepam is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Bupivacaine. Approved, Investigational Buprenorphine Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Flurazepam. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Flurazepam. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Flurazepam is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Flurazepam is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Flurazepam is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Flurazepam. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Flurazepam is combined with Canertinib. Investigational Carbamazepine The metabolism of Flurazepam can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Flurazepam is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Flurazepam is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Flurazepam is combined with Carisoprodol. Approved Ceritinib The serum concentration of Flurazepam can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Flurazepam is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Flurazepam is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flurazepam. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Flurazepam is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flurazepam. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorzoxazone. Approved Cinchocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Cinchocaine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Flurazepam is combined with Citalopram. Approved Clarithromycin The metabolism of Flurazepam can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Flurazepam can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Flurazepam is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Flurazepam is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Flurazepam is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Flurazepam is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Flurazepam. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Flurazepam is combined with Clothiapine. Experimental Clotrimazole The metabolism of Flurazepam can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Flurazepam is combined with Clozapine. Approved Cobicistat The metabolism of Flurazepam can be decreased when combined with Cobicistat. Approved Cocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Flurazepam. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Flurazepam. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Flurazepam. Approved, Investigational Crizotinib The metabolism of Flurazepam can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Flurazepam can be decreased when combined with Curcumin. Approved, Investigational Cyclizine The risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Flurazepam can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Flurazepam is combined with Cyproheptadine. Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flurazepam. Approved Dabrafenib The serum concentration of Flurazepam can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Flurazepam is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dapoxetine. Investigational Darunavir The metabolism of Flurazepam can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Flurazepam can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Flurazepam can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Flurazepam can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Flurazepam is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Flurazepam is combined with Desflurane. Approved Desipramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Flurazepam is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Flurazepam is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Flurazepam is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Flurazepam is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Flurazepam is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Diazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Flurazepam is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Flurazepam is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydrocodeine. Approved, Illicit Dihydroergotamine The metabolism of Flurazepam can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Flurazepam can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Flurazepam is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Flurazepam is combined with Diphenoxylate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Flurazepam is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Flurazepam is combined with Doxepin. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Flurazepam. Approved, Investigational Doxycycline The metabolism of Flurazepam can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Flurazepam is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved, Illicit Dronedarone The metabolism of Flurazepam can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Flurazepam is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Flurazepam is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Flurazepam is combined with Dyclonine. Approved Dyphylline The therapeutic efficacy of Flurazepam can be decreased when used in combination with Dyphylline. Approved Ecgonine The risk or severity of adverse effects can be increased when Flurazepam is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Flurazepam is combined with Ecopipam. Investigational Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Flurazepam. Approved Efavirenz The risk or severity of adverse effects can be increased when Flurazepam is combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Flurazepam is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Flurazepam is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Flurazepam is combined with Entacapone. Approved, Investigational Enzalutamide The serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide. Approved Erythromycin The metabolism of Flurazepam can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Flurazepam is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Flurazepam. Approved, Investigational Ethanol Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Flurazepam is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Flurazepam is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Flurazepam is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Flurazepam is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Flurazepam is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Flurazepam is combined with Etorphine. Illicit, Vet Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Flurazepam. Approved Ezogabine The risk or severity of adverse effects can be increased when Flurazepam is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Flurazepam is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Flurazepam is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Flurazepam is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Flurazepam is combined with Fexofenadine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flurazepam is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Flurazepam is combined with Fluanisone. Experimental Fluconazole The metabolism of Flurazepam can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flurazepam is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flurazepam is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Flurazepam. Approved Fluspirilene The risk or severity of adverse effects can be increased when Flurazepam is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Flurazepam is combined with Fluticasone propionate. Approved Fluvoxamine The metabolism of Flurazepam can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The serum concentration of Flurazepam can be increased when it is combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Flurazepam can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Flurazepam. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Flurazepam is combined with Fospropofol. Approved, Illicit, Investigational Fusidic Acid The serum concentration of Flurazepam can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Flurazepam is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Flurazepam is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Flurazepam is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Flurazepam is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Flurazepam. Approved Halothane The risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Flurazepam is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Flurazepam is combined with Hexobarbital. Approved Hyaluronidase The therapeutic efficacy of Flurazepam can be decreased when used in combination with Hyaluronidase. Approved, Investigational Hydrocodone Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Flurazepam. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved Idelalisib The metabolism of Flurazepam can be decreased when combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Flurazepam is combined with Iloperidone. Approved Imatinib The metabolism of Flurazepam can be decreased when combined with Imatinib. Approved Imipramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Flurazepam is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Flurazepam can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Flurazepam is combined with Indiplon. Investigational Isavuconazole The serum concentration of Flurazepam can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Flurazepam can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid The therapeutic efficacy of Flurazepam can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Flurazepam is combined with Isoflurane. Approved, Vet Approved Isradipine The metabolism of Flurazepam can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Flurazepam can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Flurazepam can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Flurazepam is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Flurazepam is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Flurazepam is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Flurazepam can be decreased when combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Flurazepam is combined with Lamotrigine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Flurazepam. Approved Levetiracetam The risk or severity of adverse effects can be increased when Flurazepam is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Flurazepam is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Flurazepam is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Flurazepam is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Flurazepam is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Flurazepam is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Flurazepam is combined with Levorphanol. Approved Lidocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Lidocaine. Approved, Vet Approved Lithium cation The risk or severity of adverse effects can be increased when Flurazepam is combined with Lithium. Experimental Lofentanil The risk or severity of adverse effects can be increased when Flurazepam is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Flurazepam can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Flurazepam can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Flurazepam is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Flurazepam is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Flurazepam. Approved Lormetazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Flurazepam can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Flurazepam can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Flurazepam. Approved Luliconazole The serum concentration of Flurazepam can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Flurazepam can be increased when combined with Lumacaftor. Approved Lurasidone The risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Flurazepam can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Flurazepam is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Flurazepam is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Flurazepam is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Flurazepam is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Flurazepam is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone. Approved Methadone Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Flurazepam is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Flurazepam is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Flurazepam is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Flurazepam. Approved Methotrimeprazine Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Flurazepam is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Flurazepam is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Flurazepam is combined with Methylphenobarbital. Approved Metyrosine Flurazepam may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Flurazepam. Approved, Illicit Mifepristone The serum concentration of Flurazepam can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Flurazepam is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved, Investigational Mirtazapine Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Flurazepam can be decreased when it is combined with Mitotane. Approved Molindone The risk or severity of adverse effects can be increased when Flurazepam is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Flurazepam. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Flurazepam is combined with Nalbuphine. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Flurazepam. Approved Nefazodone The metabolism of Flurazepam can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Flurazepam can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Flurazepam can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Flurazepam can be increased when combined with Nevirapine. Approved Nicotine The metabolism of Flurazepam can be decreased when combined with Nicotine. Approved Nilotinib The metabolism of Flurazepam can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Flurazepam is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Flurazepam is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Flurazepam is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Flurazepam is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Flurazepam is combined with Olanzapine. Approved, Investigational Olaparib The metabolism of Flurazepam can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Flurazepam is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Flurazepam is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Flurazepam is combined with Opium. Approved, Illicit Orphenadrine Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Flurazepam is combined with Osanetant. Investigational Osimertinib The serum concentration of Flurazepam can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Oxazepam. Approved Oxprenolol The risk or severity of adverse effects can be increased when Flurazepam is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Flurazepam. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Flurazepam is combined with Oxymorphone. Approved, Investigational, Vet Approved Palbociclib The serum concentration of Flurazepam can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Flurazepam is combined with Paliperidone. Approved Paraldehyde Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Flurazepam. Approved Penfluridol The risk or severity of adverse effects can be increased when Flurazepam is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Flurazepam. Approved, Vet Approved Pentobarbital The metabolism of Flurazepam can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved Perazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Flurazepam is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Perphenazine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Flurazepam. Approved Phenazocine The risk or severity of adverse effects can be increased when Flurazepam is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Flurazepam is combined with Phenibut. Experimental Phenobarbital The metabolism of Flurazepam can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Flurazepam is combined with Phenoxyethanol. Approved Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Flurazepam. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Flurazepam is combined with Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Flurazepam is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Flurazepam is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Flurazepam can be decreased when it is combined with Pitolisant. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Flurazepam is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Flurazepam is combined with Pomalidomide. Approved Posaconazole The metabolism of Flurazepam can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Flurazepam may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Flurazepam can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Prilocaine. Approved Primidone The metabolism of Flurazepam can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Flurazepam is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Flurazepam is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Flurazepam is combined with Proxibarbal. Experimental Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Flurazepam. Approved PSD502 The risk or severity of adverse effects can be increased when Flurazepam is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Flurazepam is combined with Quetiapine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Flurazepam is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Flurazepam is combined with Ramelteon. Approved, Investigational Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Flurazepam. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Flurazepam is combined with Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Flurazepam is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Flurazepam. Approved, Investigational Rifabutin The metabolism of Flurazepam can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Flurazepam can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Flurazepam can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Flurazepam. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Flurazepam is combined with Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Flurazepam is combined with Ritanserin. Investigational Ritonavir The serum concentration of Flurazepam can be increased when it is combined with Ritonavir. Approved, Investigational Romifidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Romifidine. Vet Approved Ropinirole Flurazepam may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Ropivacaine. Approved Rotigotine Flurazepam may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Flurazepam can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Flurazepam. Approved Saquinavir The serum concentration of Flurazepam can be increased when it is combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Flurazepam can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Flurazepam is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Flurazepam. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Flurazepam is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Flurazepam is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Flurazepam is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Flurazepam is combined with Sevoflurane. Approved, Vet Approved Sildenafil The metabolism of Flurazepam can be decreased when combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Flurazepam. Approved Siltuximab The serum concentration of Flurazepam can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Flurazepam can be increased when it is combined with Simeprevir. Approved Sodium oxybate Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Approved St. John's Wort The serum concentration of Flurazepam can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Flurazepam can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil. Approved, Investigational Sulfisoxazole The metabolism of Flurazepam can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Flurazepam is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Flurazepam is combined with Sultopride. Experimental Suvorexant Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Flurazepam is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Flurazepam. Approved Tasimelteon The risk or severity of adverse effects can be increased when Flurazepam is combined with Tasimelteon. Approved, Investigational Teduglutide The serum concentration of Flurazepam can be increased when it is combined with Teduglutide. Approved Telaprevir The metabolism of Flurazepam can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Flurazepam can be decreased when combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Flurazepam. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrodotoxin. Investigational Thalidomide Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The therapeutic efficacy of Flurazepam can be decreased when used in combination with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Flurazepam is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Flurazepam is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Flurazepam. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Flurazepam is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Flurazepam can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab. Approved Tolcapone The risk or severity of adverse effects can be increased when Flurazepam is combined with Tolcapone. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Flurazepam is combined with Topiramate. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Flurazepam. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Flurazepam. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Flurazepam is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Flurazepam is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Flurazepam is combined with Triazolam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Flurazepam is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Flurazepam is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluoperazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Flurazepam is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Flurazepam is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Flurazepam is combined with Valproic Acid. Approved, Investigational Vemurafenib The serum concentration of Flurazepam can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Flurazepam can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Flurazepam is combined with Veralipride. Experimental Verapamil The metabolism of Flurazepam can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Flurazepam is combined with Vigabatrin. Approved Vincristine The excretion of Vincristine can be decreased when combined with Flurazepam. Approved, Investigational Vinyl ether The risk or severity of adverse effects can be increased when Flurazepam is combined with Vinyl ether. Experimental Voriconazole The metabolism of Flurazepam can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Flurazepam is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Flurazepam is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Flurazepam is combined with Xylazine. Vet Approved Yohimbine The therapeutic efficacy of Flurazepam can be decreased when used in combination with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Flurazepam is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Flurazepam is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Flurazepam is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Flurazepam can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Zolazepam. Vet Approved Zolpidem Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Flurazepam is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Flurazepam is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Flurazepam is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Flurazepam is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Take without regard to meals.
References
- Synthesis Reference
Fryer, R. and Sternbach, L.H.; U.S. Patent 3,567,710; March 2, 1971; assigned to Hoffman-La Roche, Inc.
- General References
- Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820]
- Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115]
- Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451]
- Rooke KC: The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice. J Int Med Res. 1976;4(5):355-9. [PubMed:18375]
- Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [PubMed:851373]
- Link [Link]
- External Links
- Human Metabolome Database
- HMDB0014828
- KEGG Drug
- D00329
- PubChem Compound
- 3393
- PubChem Substance
- 46508451
- ChemSpider
- 3276
- ChEBI
- 5128
- ChEMBL
- CHEMBL968
- Therapeutic Targets Database
- DAP000242
- PharmGKB
- PA449681
- HET
- FL7
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Flurazepam
- ATC Codes
- N05CD01 — Flurazepam
- AHFS Codes
- 28:24.08 — Benzodiazepines
- PDB Entries
- 2yoe
- MSDS
- Download (50.5 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Insomnia Disorder 1 3 Terminated Treatment Anxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders 1
Pharmacoeconomics
- Manufacturers
- Valeant pharmaceuticals international
- Halsey drug co inc
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Par pharmaceutical inc
- Purepac pharmaceutical co
- Sandoz inc
- Superpharm corp
- Usl pharma inc
- Warner chilcott inc
- Warner chilcott div warner lambert co
- Watson laboratories inc
- West ward pharmaceutical corp
- Packagers
- Amerisource Health Services Corp.
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Corepharma LLC
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- H.J. Harkins Co. Inc.
- Hl Moore Drug Exchange
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Legacy Pharmaceuticals Packaging LLC
- Major Pharmaceuticals
- Mylan
- Nucare Pharmaceuticals Inc.
- Par Pharmaceuticals
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Rebel Distributors Corp.
- Remedy Repack
- Southwood Pharmaceuticals
- UDL Laboratories
- Valeant Ltd.
- West-Ward Pharmaceuticals
- Dosage forms
Form Route Strength Capsule Oral 30 mg/1 Capsule Oral 30 mg Capsule Oral 15 mg Capsule Oral 15 mg/1 Tablet Oral 15 mg Tablet Oral 30 mg - Prices
Unit description Cost Unit Dalmane 30 mg capsule 2.01USD capsule Dalmane 15 mg capsule 1.79USD capsule Flurazepam HCl 15 mg capsule 0.43USD capsule Flurazepam HCl 30 mg capsule 0.4USD capsule Flurazepam 30 mg capsule 0.34USD capsule Flurazepam 15 mg capsule 0.28USD capsule Apo-Flurazepam 30 mg Capsule 0.1USD capsule Apo-Flurazepam 15 mg Capsule 0.08USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 190-220 British Patent 1,040,548. water solubility 500 mg/mL (HCl salt) Not Available logP 3.8 Not Available - Predicted Properties
Property Value Source Water Solubility 0.01 mg/mL ALOGPS logP 3.81 ALOGPS logP 3.95 ChemAxon logS -4.6 ALOGPS pKa (Strongest Basic) 8.71 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 35.91 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 107.54 m3·mol-1 ChemAxon Polarizability 41.22 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9898 Caco-2 permeable + 0.6115 P-glycoprotein substrate Substrate 0.8553 P-glycoprotein inhibitor I Inhibitor 0.9455 P-glycoprotein inhibitor II Inhibitor 0.6624 Renal organic cation transporter Inhibitor 0.6523 CYP450 2C9 substrate Non-substrate 0.7716 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Substrate 0.7794 CYP450 1A2 substrate Inhibitor 0.5194 CYP450 2C9 inhibitor Non-inhibitor 0.7112 CYP450 2D6 inhibitor Non-inhibitor 0.5469 CYP450 2C19 inhibitor Inhibitor 0.5082 CYP450 3A4 inhibitor Inhibitor 0.6347 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6231 Ames test Non AMES toxic 0.9132 Carcinogenicity Non-carcinogens 0.7597 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.5654 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9528 hERG inhibition (predictor II) Inhibitor 0.7183
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzodiazepines
- Sub Class
- 1,4-benzodiazepines
- Direct Parent
- 1,4-benzodiazepines
- Alternative Parents
- Alpha amino acids and derivatives / Fluorobenzenes / Aryl chlorides / Aryl fluorides / Tertiary carboxylic acid amides / Trialkylamines / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds show 6 more
- Substituents
- 1,4-benzodiazepine / Alpha-amino acid or derivatives / Halobenzene / Fluorobenzene / Aryl chloride / Monocyclic benzene moiety / Benzenoid / Aryl fluoride / Aryl halide / Tertiary carboxylic acid amide show 24 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA4
- Uniprot ID
- P48169
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-4
- Molecular Weight
- 61622.645 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA6
- Uniprot ID
- Q16445
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-6
- Molecular Weight
- 51023.69 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB1
- Uniprot ID
- P18505
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-1
- Molecular Weight
- 54234.085 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB2
- Uniprot ID
- P47870
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-2
- Molecular Weight
- 59149.895 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-gated chloride ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB3
- Uniprot ID
- P28472
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-3
- Molecular Weight
- 54115.04 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG1
- Uniprot ID
- Q8N1C3
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-1
- Molecular Weight
- 53594.49 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRG2
- Uniprot ID
- P18507
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-2
- Molecular Weight
- 54161.78 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG3
- Uniprot ID
- Q99928
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-3
- Molecular Weight
- 54288.16 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRD
- Uniprot ID
- O14764
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit delta
- Molecular Weight
- 50707.835 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRE
- Uniprot ID
- P78334
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit epsilon
- Molecular Weight
- 57971.175 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
- Gene Name
- GABRP
- Uniprot ID
- O00591
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit pi
- Molecular Weight
- 50639.735 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
- Gene Name
- GABRR1
- Uniprot ID
- P24046
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-1
- Molecular Weight
- 55882.91 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
- Gene Name
- GABRR2
- Uniprot ID
- P28476
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-2
- Molecular Weight
- 54150.41 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRR3
- Uniprot ID
- A8MPY1
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-3
- Molecular Weight
- 54271.1 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transmembrane signaling receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRQ
- Uniprot ID
- Q9UN88
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit theta
- Molecular Weight
- 72020.875 Da
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6. [PubMed:1971572]
- Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20. [PubMed:18936109]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6. [PubMed:1971572]
- Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20. [PubMed:18936109]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Zolk O, Solbach TF, Konig J, Fromm MF: Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun;37(6):1312-8. doi: 10.1124/dmd.108.023762. Epub 2009 Feb 27. [PubMed:19251820]
Drug created on June 13, 2005 07:24 / Updated on July 13, 2018 01:02